Your browser version may not work well with NCBI's Web applications. More information here...
1: Hepatogastroenterology. 2007 Dec;54(80):2373-7.Links

Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.

Milandri C, Calzolari F, Passardi A, Tison C, Giampalma E, Cecconetto L, Golfieri R.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy. res.onco@ausl.fo.it

BACKGROUND/AIMS: The main aim of the present work was to determine response rates and time to progression in patients with locally advanced or metastatic pancreatic cancer treated with intra-arterial chemotherapy. METHODOLOGY: Nineteen chemotherapy-naive patients with measurable lesions were treated with intra-arterial 5-fluorouracil 1000 mg/m2, leucovorin 100 mg/m2, carboplatin 300 mg/m2 and epirubicin 60 mg/m2 (FLEC regimen) every 21 days. Prophylactic granulocyte colony-stimulating factors were administered on days 4-10 of each cycle. RESULTS: There were 16 patients evaluable for response, of whom 4 (25%) had a partial response, 7 (44%) showed stable disease, and 5 (31%) progressed. Marker response rate was 43%. Median time to progression was 4 months and median overall survival was 6 months. One-year overall survival was 16%. No grade 4 toxicity or severe complications relating to the angiographic procedure were observed. CONCLUSIONS: Our results show that intra-arterial FLEC is well tolerated and active against advanced pancreatic cancer.

PMID: 18265668 [PubMed - indexed for MEDLINE]

Patient Drug Information